Cell Reports,
Год журнала:
2025,
Номер
44(2), С. 115314 - 115314
Опубликована: Фев. 1, 2025
Repeated
vaccinations
and
infections
have
led
to
diverse
states
of
hybrid
immunity
against
SARS-CoV-2
in
the
global
population.
However,
age
comorbidities
can
compromise
protection
severe
disease,
antibody-mediated
is
undercut
by
viral
immune
escape
mutations.
Whether
what
extent
durable
T
cell
responses
compensate
for
reduced
humoral
immunity,
particularly
elderly,
not
been
investigated.
Here,
we
utilize
SARS-CoV-2-specific
pan-coronavirus-derived
peptide
pools,
including
or
excluding
spike
glycoprotein-derived
epitopes,
measure
vaccination
infection
induced
pan-human
endemic
coronavirus
(PHEC)-directed
immunity.
In
contrast
vaccinated
individuals,
comprises
high
frequencies
PHEC-reactive
cells
with
comparable
functional
TCR
avidities
across
all
groups.
With
waning
vulnerability
mutations,
may
provide
critical
protection.
Our
findings
underscore
importance
incorporating
pan-coronavirus
epitopes
future
vaccine
strategies.
Science Immunology,
Год журнала:
2022,
Номер
7(76)
Опубликована: Июль 19, 2022
SARS-CoV-2
mRNA
vaccination
induces
robust
humoral
and
cellular
immunity
in
the
circulation;
however,
it
is
currently
unknown
whether
elicits
effective
immune
responses
respiratory
tract,
particularly
against
variants
of
concern
(VOCs),
including
Omicron.
We
compared
S-specific
total
neutralizing
antibody
responses,
B
T
cell
immunity,
bronchoalveolar
lavage
fluid
(BAL)
blood
COVID-19-vaccinated
individuals
hospitalized
patients.
Vaccinated
had
significantly
lower
levels
D614G,
Delta
(B.1.617.2),
Omicron
BA.1.1
BAL
with
COVID-19
convalescents
despite
blood.
Furthermore,
induced
circulating
but
contrast
to
convalescents,
these
were
absent
vaccinated
individuals.
Using
a
mouse
immunization
model,
we
demonstrated
that
systemic
alone
weak
mucosal
especially
mice;
combination
plus
adenovirus-S
strong
not
only
ancestral
virus
also
variant.
Together,
our
study
supports
contention
current
vaccines
are
highly
severe
disease
development,
likely
through
recruiting
during
reinfection,
offer
limited
protection
breakthrough
infection,
by
sublineage.
Hence,
booster
needed
establish
sterilizing
tract
SARS-CoV-2,
infection
sublineage
future
VOCs.
Science,
Год журнала:
2022,
Номер
378(6620), С. 619 - 627
Опубликована: Окт. 20, 2022
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
Omicron
sublineages
carry
distinct
spike
mutations
resulting
in
escape
from
antibodies
induced
by
previous
infection
or
vaccination.
We
show
that
hybrid
immunity
vaccine
boosters
elicit
plasma-neutralizing
against
BA.1,
BA.2,
BA.2.12.1,
and
BA.4/5,
breakthrough
infections,
but
not
vaccination
alone,
induce
neutralizing
the
nasal
mucosa.
Consistent
with
immunological
imprinting,
most
derived
memory
B
cells
plasma
of
cases
cross-react
Wuhan-Hu-1,
BA.4/5
receptor-binding
domains,
whereas
primary
infections
narrow
specificity
up
to
6
months
after
infection.
Although
clinical
have
reduced
neutralization
Omicron,
we
identified
an
ultrapotent
pan-variant–neutralizing
antibody
is
a
strong
candidate
for
development.
Annual Review of Immunology,
Год журнала:
2023,
Номер
41(1), С. 343 - 373
Опубликована: Фев. 8, 2023
A
large
body
of
evidence
generated
in
the
last
two
and
a
half
years
addresses
roles
T
cells
SARS-CoV-2
infection
following
vaccination.
Infection
or
vaccination
induces
multi-epitope
CD4
CD8
cell
responses
with
polyfunctionality.
Early
have
been
associated
mild
COVID-19
outcomes.
In
concert
animal
model
data,
these
results
suggest
that
while
antibody
are
key
to
prevent
infection,
may
also
play
valuable
reducing
disease
severity
controlling
infection.
memory
after
is
sustained
for
at
least
six
months.
While
neutralizing
impacted
by
variants,
most
preserved.
This
review
highlights
extensive
progress
made,
data
knowledge
gaps
remain,
our
understanding
vaccines.
On
November
7th
and
8th,
2022,
The
National
Institute
of
Allergy
Infectious
Diseases
(NIAID),
part
the
Institutes
Health
(NIH),
Coalition
for
Epidemic
Preparedness
Innovation
(CEPI),
Bill
&
Melinda
Gates
Foundation
(BMGF),
Biomedical
Advanced
Research
Development
Authority
(BARDA),
Wellcome
Trust
hosted
a
virtual
workshop
entitled
"Mucosal
Vaccines
SARS-CoV-2:
Scientific
Gaps
Opportunities."
During
workshop,
researchers
vaccine
developers
from
around
world
discussed
potential
mucosal
vaccines
to
block
SARS-CoV-2
transmission
reviewed
status
research.
Here,
we
summarize
key
challenges
opportunities
in
basic,
translational,
clinical
research
that
were
highlighted
during
meeting.
We
also
provide
recommendations
advance
field
accelerate
development
SARS-CoV-2.
EBioMedicine,
Год журнала:
2023,
Номер
92, С. 104585 - 104585
Опубликована: Май 3, 2023
Currently
approved
COVID-19
vaccines
administered
parenterally
induce
robust
systemic
humoral
and
cellular
responses.
While
highly
effective
against
severe
disease,
there
is
reduced
effectiveness
of
these
in
preventing
breakthrough
infection
and/or
onward
transmission,
likely
due
to
poor
immunity
elicited
at
the
respiratory
mucosa.
As
such,
has
been
considerable
interest
developing
novel
mucosal
that
engenders
more
localised
immune
responses
provide
better
protection
recall
site
virus
entry,
contrast
traditional
vaccine
approaches
focus
on
immunity.
In
this
review,
we
explore
adaptive
components
immunity,
evaluate
epidemiological
studies
dissect
if
conferred
by
parenteral
vaccination
or
drives
differential
efficacy
acquisition
discuss
undergoing
clinical
trials
assess
key
challenges
prospects
for
development.
